Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.
Term
Q3 2026
“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”
Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.
Evofem Biosciences Debt Financing Update with Adjuvant Global Health Technology Fund, L.P.
Evofem Biosciences entered into a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment extends the maturity date of outstanding convertible promissory notes to December 1, 2026, and removes certain affirmative covenants.
Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical Limited to establish a second production source for its contraceptive gel, PHEXX. The expansion is designed to enhance supply chain flexibility and is expected to reduce unit costs by 40% or more once regulatory approval for the new facility is obtained.